Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers

Dae Seok Kim, Cristel V. Camacho, Rohit Setlem, Kangsan Kim, Srinivas Malladi, Tim Y. Hou, Tulip Nandu, Shrikanth S. Gadad, W. Lee Kraus

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Long noncoding RNAs have been implicated in many of the hallmarks of cancer. Herein, we found that the expression of lncRNA152 (lnc152; a.k.a. DRAIC), which we annotated previously, is highly upregulated in luminal breast cancer (LBC) and downregulated in triple-negative breast cancer (TNBC). Knockdown of lnc152 promotes cell migration and invasion in LBC cell lines. In contrast, ectopic expression of lnc152 inhibits growth, migration, invasion, and angiogenesis in TNBC cell lines. In mice, lnc152 inhibited the growth of TNBC cell xenografts, as well as metastasis of TNBC cells in an intracardiac injection model. Transcriptome analysis of the xenografts indicated that lnc152 downregulates genes controlling angiogenesis. Using pull down assays followed by LC/MS-MS, we identified RBM47, a known tumor suppressor in breast cancer, as a lnc152-interacting protein. The effects of lnc152 in TNBC cells are mediated, in part, by regulating the expression of RBM47. Collectively, our results demonstrate that lnc152 is an angiogenesis-inhibiting tumor suppressor that attenuates the aggressive cancer-related phenotypes found in TNBC.

Original languageEnglish (US)
Pages (from-to)1623-1635
Number of pages13
JournalMolecular Cancer Research
Volume20
Issue number11
DOIs
StatePublished - Nov 2022

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers'. Together they form a unique fingerprint.

Cite this